The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Anti-tumour antibodies.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Anti-tumour antibodies is a key innovation area in immuno-oncology
Monoclonal antibodies (mAbs) are immune system proteins that are created in the lab. MAbs, like all antibodies, contain a highly specific binding site that enables attachment to specific antigens. Mabs for cancer therapy typically bind to antigens which are expressed on the surface of tumour cells. mAbs can be used in their simple form or can be used to make other mAb-based therapeutics including, antibody-drug conjugates (ADCs), bispecific antibodies, and nanobodies.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-tumour antibodies.
Key players in anti-tumour antibodies – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to anti-tumour antibodies
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|F. Hoffmann-La Roche||1153||Unlock company profile|
|Gilead Sciences||291||Unlock company profile|
|Daiichi Sankyo||249||Unlock company profile|
|Pfizer||235||Unlock company profile|
|Amgen||206||Unlock company profile|
|Bristol-Myers Squibb||199||Unlock company profile|
|AbbVie||176||Unlock company profile|
|ImmunoGen||168||Unlock company profile|
|Seagen||166||Unlock company profile|
|Astellas Pharma||161||Unlock company profile|
|Immatics||159||Unlock company profile|
|Toray Industries||157||Unlock company profile|
|AstraZeneca||129||Unlock company profile|
|Stemcentrx||112||Unlock company profile|
|Sorrento Therapeutics||110||Unlock company profile|
|Oxford BioTherapeutics||103||Unlock company profile|
|ADC Therapeutics||75||Unlock company profile|
|TRON gGmbH||70||Unlock company profile|
|C. H. Boehringer Sohn||69||Unlock company profile|
|Alethia Biotherapeutics||69||Unlock company profile|
|Merck & Co||63||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||63||Unlock company profile|
|Chiome Bioscience||60||Unlock company profile|
|Sesen Bio||60||Unlock company profile|
|GSK||57||Unlock company profile|
|Jiangsu Hengrui Medicine||54||Unlock company profile|
|Eureka Therapeutics||51||Unlock company profile|
|Regeneron Pharmaceuticals||43||Unlock company profile|
|National Research Council of Canada||43||Unlock company profile|
|Molecular Templates||42||Unlock company profile|
|Adicet Bio||41||Unlock company profile|
|Centre National de la Recherche Scientifique||41||Unlock company profile|
|OBI Pharma||38||Unlock company profile|
|Helix BioPharma||36||Unlock company profile|
|National Cancer Center||36||Unlock company profile|
|United States Of America||34||Unlock company profile|
|TRACON Pharmaceuticals||33||Unlock company profile|
|Sanofi||31||Unlock company profile|
|Celldex Therapeutics||26||Unlock company profile|
|Les Laboratoires Servier||25||Unlock company profile|
|Merus||24||Unlock company profile|
|Revitope Oncology||23||Unlock company profile|
|Singh Molecular Medicine||23||Unlock company profile|
|Zymeworks||23||Unlock company profile|
|Fujifilm Holdings||23||Unlock company profile|
|Eli Lilly and||23||Unlock company profile|
|Development Center for Biotechnology||22||Unlock company profile|
|Oncomatryx Biopharma||22||Unlock company profile|
|Singh Biotechnology||22||Unlock company profile|
|JSR||21||Unlock company profile|
Source: GlobalData Patent Analytics
F. Hoffmann-La Roche is one of the leading patent filers in the field of anti-tumour antibodies. It is investigating multiple mAb therapeutics, which are in various stages of development. Genentech (subsidiary of F. Hoffmann-La Roche) entered an agreement with Biogen to develop and commercialise mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for the treatment of B-cell non-Hodgkin’s lymphoma and other cancer indications.
Some other key patent filers in the anti-tumour antibody area include Gilead Sciences, Daiichi Sankyo, Pfizer, Amgen, and Bristol-Myers Squibb.
In terms of application diversity, TRACON Pharmaceuticals is the top company followed by AstraZeneca and Development Center for Biotechnology. By geographic reach, Singh Molecular Medicine holds the top position. Singh Biotechnology and Centre National de la Recherche Scientifique are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.